Kiora Pharmaceuticals, Inc. (KPRX)
KPRX Stock Price Chart
Explore Kiora Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze KPRX price movements and trends.
KPRX Company Profile
Discover essential business fundamentals and corporate details for Kiora Pharmaceuticals, Inc. (KPRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
13 Feb 2015
Employees
12.00
Website
https://www.kiorapharma.comCEO
Brian Strem
Description
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
KPRX Financial Timeline
Browse a chronological timeline of Kiora Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 7 Aug 2026
EPS estimate is -$0.47.
Earnings released on 8 May 2026
EPS came in at -$0.58 surpassing the estimated -$0.71 by +18.31%.
Earnings released on 25 Mar 2026
EPS came in at -$1.60 falling short of the estimated -$0.67 by -138.81%.
Earnings released on 7 Nov 2025
EPS came in at $0.01 surpassing the estimated -$0.72 by +101.39%.
Earnings released on 8 Aug 2025
EPS came in at -$0.54 surpassing the estimated -$0.58 by +6.90%.
Earnings released on 9 May 2025
EPS came in at -$0.52 surpassing the estimated -$0.77 by +32.47%.
Earnings released on 25 Mar 2025
EPS came in at -$1.04 falling short of the estimated -$0.64 by -62.50%.
Earnings released on 8 Nov 2024
EPS came in at -$0.81 surpassing the estimated -$0.90 by +10.00%.
Earnings released on 9 Aug 2024
EPS came in at -$0.53 surpassing the estimated -$0.95 by +44.21%, while revenue for the quarter reached $20.00k .
Stock split effective on 11 Jun 2024
Shares were split 1 : 9 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 May 2024
EPS came in at $3.42 falling short of the estimated $5.58 by -38.71%, while revenue for the quarter reached $16.00m , meeting expectations.
Earnings released on 28 Mar 2024
EPS came in at -$0.47 falling short of the estimated -$0.42 by -11.90%, while revenue for the quarter reached $283.87k .
Earnings released on 9 Nov 2023
EPS came in at -$8.01 falling short of the estimated -$2.70 by -196.67%.
Earnings released on 8 Aug 2023
EPS came in at -$7.11 falling short of the estimated -$4.59 by -54.90%.
Earnings released on 9 May 2023
EPS came in at -$1.00 surpassing the estimated -$1.68 by +40.48%.
Earnings released on 23 Mar 2023
EPS came in at -$1.76 surpassing the estimated -$2.46 by +28.46%.
Earnings released on 9 Nov 2022
EPS came in at -$39.15 falling short of the estimated -$3.83 by -922.19%.
Stock split effective on 27 Sept 2022
Shares were split 1 : 40 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 Aug 2022
EPS came in at -$64.81 surpassing the estimated -$72.01 by +10.00%.
Earnings released on 8 Jul 2022
EPS came in at -$97.21 falling short of the estimated -$9.20 by -956.63%.
Earnings released on 15 Apr 2022
EPS came in at -$280.83 .
Earnings released on 15 Nov 2021
EPS came in at -$104.41 surpassing the estimated -$122.41 by +14.70%.
Earnings released on 12 Aug 2021
EPS came in at -$14.00 surpassing the estimated -$16.67 by +16.02%.
KPRX Stock Performance
Access detailed KPRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
